Thu, Apr. 30, 4:08 PM
- According to Bloomberg, the list of firms that have indicated an interest in Omnicare (NYSE:OCR) include Express Scripts (NASDAQ:ESRX), CVS Health (NYSE:CVS), Walgreens Boots Alliance (NASDAQ:WBA) and McKesson (NYSE:MCK). Initial bids for the $8.5B market cap firm are due in May.
- Previously: Omnicare reportedly exploring sale; trading halted (April 22)
- Previously: Omnicare buyer would need to pay $95/share - UBS (April 23)
Thu, Apr. 23, 7:41 AM
- UBS estimates a buyer would have to pay $95 to acquire Omnicare (NYSE:OCR).
- Firm thinks Walgreens (NASDAQ:WBA) or Rite Aid (NYSE:RAD) could be interested, but are unlikely to pay up due to limited synergies.
- OCR increased management comp. in the event of a change in control, a possible indicator the company may be sold.
- Previously: Omnicare reportedly exploring sale; trading halted (Apr. 22)
Tue, Mar. 24, 10:25 AM
- A merger between Walgreens Boots Alliance (WBA -0.3%) and Rite Aid (RAD +1.3%) would lead to cost savings of between $400M and $650M, according to analysis from Credit Suisse.
- The investment firm also forecasts the merged drugstore operator would have to shed 3% of its stores to appease the FTC.
- RetailWire notes the new company would face some challenges with unions and higher borrowing costs.
- Rite Aid is up over 13% over the last month due in part to merger speculation.
- Previously: Walgreen Boots Alliance eyes U.S. drugstore acquisition (Mar. 12 2015)
- Previously: No quit in Walgreens-Rite Aid merger talk (Mar. 19 2015)
Thu, Mar. 19, 10:06 AM
- Shares of Rite Aid (RAD +3.8%) are higher again to extend on a rally fueled by Walgreens takeover rumors.
- Volume on Rite Aid over the last few sessions has been very elevated.
- Walgreen Boots Alliance (NASDAQ:WBA) is up over 6.6% for the week as investors don't scare off from the prospect of the company taking on the Rite Aid debt load.
- A big bet on Rite Aid is seen as a smarter play than buying up mom-and-pop chains.
Thu, Mar. 12, 2:33 PM
- Walgreen Boots Alliance (WBA +1.5%) is on the hunt for an acquisition in the U.S., according to the company's acting CEO
- "The next big one will probably be in the U.S. because it is such a big market," said Stefano Pessina at a retail conference.
- Shares of WBA are +9.8% since the Alliance Boots-Walgreen merger.
Sep. 24, 2014, 1:45 AM
- Walgreen (NYSE:WAG) is considering the sale of just over 50% of its infusion services business, in a deal that could value the unit at around $1.5B.
- The division offers infusion services at home and at care centers across the U.S. Infusion therapies are used for medical conditions such as bleeding disorders and serious infections.
- BofA has been hired by Walgreen for the sale, which has already attracted interest from several private equity firms.
May 18, 2014, 4:07 AM
- Walgreen (WAG) is thinking about buying the 55% in European peer Alliance Boots it doesn't own, The Sunday Times reports.
- Taking inspiration from Pfizer in its pursuit of AstraZeneca, Walgreen would then move its domicile to the U.K. or Switzerland in order to lower its tax rate and save billions of dollars a year.
- Walgreen purchased 45% of Boots in 2012 in a cash-and-stock deal worth $6.7B and has a three-year option to acquire the rest.
Feb. 28, 2014, 12:49 PM| 2 Comments
Nov. 27, 2013, 11:00 AM
- CVS Caremark's (CVS) agreement to acquire Coram, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group, for approximately $2.1B will strengthen its position relative to market leader Walgreens (WAG), Wells Fargo says.
- "This transaction should strengthen CVS' positioning in the specialty pharmaceutical business, which we believe is increasingly critical in driving growth for the PBMs, particularly as we believe historical sources of earnings growth taper (including generics and mail order). Walgreens is currently the market leader in the specialty pharmacy business, followed closely by CVS and the acquisition of Coram should strengthen CVS' positioning."
- "Prior to Caremark being solely a PBM, it was one of the largest home infusion therapy companies in the country, but Caremark sold these assets in 1995 to Coram for about $310M in cash and preferred stock, with estimated revenues of under $500M. Today's announcement will bring back this business despite the now resolved litigated history regarding the original sale, though Coram is now considerably larger and includes ambulatory infusion sites."
- Coram peer BioScrip (BIOS) is +20% today, a move that appears directly related to the acquisition of Coram.
Sep. 10, 2013, 9:54 AM
- Walgreen (WAG +0.2%) has agreed to acquire 76 retail drugstores and the specialty pharmacy business of Kerr Drugs, a privately held regional chain in North Carolina. The deal also includes a distribution center, although Kerr will retain its long-term care pharmacy business.
- While terms of the purchase weren't disclosed, Walgreen said Kerr's drugstores and specialty pharmacy operations generated sales of $381M in FY 2012.
- The deal expands Walgreen's presence in the "fast-growing" market of North Carolina, including into many smaller communities.
- Walgreen expects the transaction to close this year. (PR)
May 17, 2013, 12:48 PM
Dec. 13, 2012, 12:46 PMBioScrip (BIOS +1.7%) moves up after announcing earlier today that it was buying infusion pharmacy services provider HomeChoice Partners for $70M in cash from DaVita HealthCare Partners (DVA -0.3%). The deal is part of a larger effort by BIOS to expand its national footprint. In February, it sold its specialty and mail-service pharmacy operations to Walgreen (WAG)for $225M, saying it wanted to turn its focus onto building its alternate-site infusion business. | Comment!
Jul. 5, 2012, 8:20 AMWalgreen (WAG) announces that it will acquire regional drugstore chain from the LaFrance family for $438M. The transaction includes stores running under the USA Drug, Super D Drug, Mays Drug, Med-X and Drug Warehouse banner. The company also reports that June same-store sales decreased 10.0% after generic introductions and the Express Scripts dispute adversely affected results. Shares -0.9% premarket. | Comment!
Jun. 21, 2012, 1:08 PMWhile Walgreen's (WAG +0.1%) proposed $6.7B bet on Europe-based Alliance Boots sparked a sell-off in its shares, Smead Capital's Bill Smead says the move will look "pretty darn smart" once the region recovers. With everyone "afraid to take risks, this may be the first step in establishing global drugstore chains," Smead says.
Apr. 2, 2012, 11:10 AMExpress Scripts (ESRX +3.3%) completes its $29.1B purchase of Medco (MHS -1.3%) following the FTC's approval of the deal. Three senior Medco execs will join Express' top team, although that doesn't incldue Medco CEO David Snow. Despite its dispute with Express, Walgreen's (WAG +2.3%) contract with Medco will be honored. | 1 Comment
Mar. 14, 2012, 10:29 AMRite Aid (RAD +6.4%) shares surge as Credit Suisse suggests a Walgreen (WAG) acquisition of the drugstore chain would make sense strategically given its contact dispute with Express Scripts and CVS and reimbursement rate pressures. Putting the odds of a deal at one in three, the firm says it would create significant synergies and not likely to raise major antitrust concerns. | 1 Comment
WBA vs. ETF Alternatives
Walgreens Boots Alliance Inc operates drug-stores chain in the United States. It provides consumer goods and services, pharmacy, and health and wellness services through drug-stores, as well as mail, and by telephone and online.
Other News & PR